Finished
Research Projects
ARCoV-005
A global, multi-center, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the protective efficacy, safety and immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in population aged 18 years and older
Proxalutamide
A randomized, double-blind, placebo-controlled, phase III study to evaluate the efficacy and safety of proxalutamide (GT0918) in hospitalized COVID-19 subjects.
hzVSF-v13 (ImmuneMed)
hzVSF-v13_0007 trial is a multicenter phase 2 randomized control trial to evaluate the efficacy and safety of a novel anti-vimentin monoclonal antibody for moderate to severe COVID-19 patients.
TRUNCATE-TB
Two-Month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-Sensitive Tuberculosis
A Phase II clinical trial evaluating the efficacy and safety of BDB-001, an investigational recombinant humanized IgG4 monoclonal antibody, for the treatment of severe and progressive COVID-19. The study explores BDB-001 as a targeted immunomodulatory therapy aimed at improving clinical outcomes in hospitalized patients.
AVIMAC
A Randomized, Open label, Controlled Study to Evaluate Efficacy and Tolerability of the Administration of AVIMAC as Adjuvant Treatment in Mild or Moderate COVID-19 Patients who Receive the Standard Treatment
BDB-001
Monovalent
BA 4/5 Phase 1, 2/3
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy, Safety, and Immunogenicity of SARS- CoV-2 Variant (BA.4/5) mRNA Vaccine (ABO1020) in Healthy Subjects Aged 18 Years and Older Who Have Completed the Full Vaccination
A Randomized, Double-Blind, and Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO-CoV.617.2) in Indonesian Subjects Aged 18 Years and Older Who Have Not Received SARS-CoV-2 Vaccines
Monovalent Phase 1 (M1)
A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults
1to3
Evaluation of Treatment Completion for Tuberculosis Preventive Treatment (TPT) Using Daily Isoniazid and Rifapentine for One Month (1HP) versus Weekly Isoniazid and Rifapentine for Three Months (3HP) among HIV-Negative Household Contacts of Bacteriologically Confirmed Pulmonary Tuberculosis Patients
M72 TB Vaccine
The Pharmaceutical Resilience Roadmap Study
A descriptive qualitative policy analysis examining Indonesia’s pharmaceutical industry ecosystem to develop a roadmap for national self-reliance and resilience in the production of essential medicines for AIDS, Tuberculosis, and Malaria (ATM).
Operational Research of Recombinant Mycobacterium Tuberculosis Fusion Protein Tuberculin Skin Test (C-TST) for Diagnosis of Latent Mycobacterium Tuberculosis Infection in Populations Aged 18 Years to 65 Years Old in Indonesia.
C-TST
Head Office Address
Jl. Balai Pustaka Barat 358E
Rawamangun, Pulo Gadung
Jakarta Timur, 13220
Any questions and inquiries, Feel free to contact us:
Contact Us
Corresponding Address
Jalan Pegambiran No. 37 lantai 2,
Rawamangun, Pulo Gadung
Jakarta Timur, 13220